Liquid Biopsy for Cancer: What Blood Samples Can Detect and What They Cannot

A liquid biopsy is a laboratory test that looks for cancer-related material in blood or another body fluid instead of removing a piece of tumour tissue. In cancer care, a liquid biopsy for cancer most often searches for circulating tumour DNA, or ctDNA—tiny fragments of DNA released by cancer cells into the bloodstream. These tests can sometimes identify genetic changes that help doctors choose targeted treatment, and researchers are also studying them for treatment monitoring, detecting residual disease, and cancer screening. The important limitation is that not every cancer releases enough detectable material into blood, especially when a tumour is small or at an early stage. A negative blood result therefore does not necessarily mean that cancer is absent, and tissue biopsy remains essential in many situations. This guide explains what liquid biopsy can reliably tell doctors today, what emerging tests may eventually do, and where the technology still falls short.

• •What Is a Liquid Biopsy for Cancer?
• •What Can a Blood-Based Liquid Biopsy Detect?
• •What Can Liquid Biopsy Not Reliably Tell You?
• •Can Liquid Biopsy Detect Cancer Early?
• •What Are the Benefits and Limitations of Liquid Biopsy?
• •When Might a Doctor Recommend a Liquid Biopsy?
• •When Is Tissue Biopsy or Further Testing Still Necessary?
• •Conclusion
• •Frequently Asked Questions

What Is a Liquid Biopsy for Cancer?

A liquid biopsy examines cancer-related biological material circulating in blood or another body fluid. Depending on the test, this material may include tumour DNA, whole circulating tumour cells, RNA, proteins, extracellular vesicles, or other biomarkers.

The most clinically developed approach is circulating tumour DNA testing. ctDNA is part of the broader pool of cell-free DNA found in the bloodstream; the challenge for the laboratory is to distinguish tiny amounts of DNA originating from cancer cells from the much larger amount released by normal cells.

The National Cancer Institute overview of liquid biopsy testing explains that these blood tests can look for cancer cells or pieces of DNA shed by tumour cells and may be used in diagnosis, treatment planning, response assessment, or surveillance depending on the clinical situation.

How is this different from a tissue biopsy?

A tissue biopsy physically removes cells or tissue from a suspicious area so that a pathologist can examine the cells and often perform molecular testing.

That information can establish what type of cancer is present, describe its microscopic appearance, and provide molecular information that may influence treatment. Tissue biopsy therefore remains the reference method for diagnosing many solid cancers.

A blood test is less invasive and easier to repeat, but it usually provides different information. It may reveal molecular signals shed from a tumour without showing the architecture of the tumour itself.

Liquid biopsy and tissue biopsy provide overlapping but different information

Feature	Liquid biopsy	Tissue biopsy
Sample	Usually blood; other body fluids may also be studied	Cells or tissue removed directly from a suspected tumour
Invasiveness	Usually minimally invasive	May require needle biopsy, endoscopy or surgery
Repeat testing	Relatively easy to repeat	Repeated sampling may be difficult or risky
Genetic information	Can detect selected tumour-related alterations if enough material reaches the blood	Can provide detailed molecular information directly from sampled tumour tissue
Tumour appearance under microscope	Cannot provide conventional tumour architecture	Allows direct pathological examination
Negative result	May be falsely negative if little or no tumour material is circulating	Usually more direct, though sampling errors can still occur
Best role	Molecular profiling, selected treatment decisions and emerging monitoring applications	Diagnosis, tumour classification and broad pathological assessment

What Can a Blood-Based Liquid Biopsy Detect?

Liquid biopsy can sometimes detect genetic alterations associated with an existing cancer and help identify treatment options. Its most established use is not finding unknown cancers in healthy people but helping manage cancers that have already been diagnosed.

Actionable cancer mutations

Some cancers contain mutations, rearrangements, amplifications, or other molecular changes that make them susceptible to targeted medicines.

Blood-based genomic profiling can search ctDNA for these alterations. FDA-authorized liquid biopsy companion diagnostics in the United States, for example, can identify certain molecular findings that help determine eligibility for particular targeted treatments.

The NCI guidance on biomarker testing for cancer treatment explains that a liquid biopsy may be considered when tumour molecular testing is needed and obtaining sufficient tissue is difficult or unsafe.

Whether a particular liquid biopsy is appropriate depends on the cancer type, the test, the biomarker being sought, previous treatment, and local regulatory approvals.

Tumour changes that emerge during treatment

Cancer is not genetically static. Tumours can acquire additional changes under treatment pressure, sometimes creating resistance to a drug that previously worked.

Because blood collection is comparatively easy to repeat, ctDNA testing may help identify evolving molecular alterations without repeatedly performing invasive biopsies. This is one of the advantages driving the use of liquid biopsy in precision oncology.

Signals of remaining cancer after treatment

Researchers are increasingly studying ctDNA for minimal or molecular residual disease, often abbreviated MRD. This means detecting extremely small amounts of cancer-related material that may remain after surgery, chemotherapy, or other treatment even when conventional imaging cannot identify a tumour.

A 2025 review in Nature Reviews Clinical Oncology described ctDNA as a promising approach for detecting and monitoring residual disease in solid tumours. However, it also emphasized that detecting extremely small amounts of cancer DNA remains technically demanding and that clinical use differs substantially between cancer types and settings.

Possible recurrence before it appears on scans

In some studies, ctDNA has become detectable before a recurrence was visible on standard imaging. This raises the possibility of identifying relapse earlier.

Earlier detection does not automatically mean that acting on that result improves survival. Researchers still need clinical trials showing when changing treatment because of a positive ctDNA result actually benefits patients.

What Can Liquid Biopsy Not Reliably Tell You?

A liquid biopsy cannot reliably rule out cancer simply because the blood test is negative. It also cannot generally replace the pathological information obtained from tumour tissue.

This is the most important limitation for patients to understand.

A negative test cannot always rule out cancer

Some tumours release very little ctDNA into the bloodstream. The amount can depend on tumour size, location, blood supply, cancer type, treatment, and overall tumour burden.

Small or early-stage tumours may release especially little material. When the cancer signal is extremely diluted among DNA from normal cells, even sophisticated tests can miss it.

For this reason, when blood-based tumour profiling fails to find a relevant alteration, tissue testing may still be recommended if it is medically feasible.

It cannot always identify exactly where a cancer is

Detecting an abnormal cancer-associated signal in blood does not necessarily tell clinicians exactly where a tumour is located.

Some newer multi-cancer detection tests attempt to predict a likely “tissue of origin,” but a positive result generally requires follow-up investigations such as imaging, endoscopy, or tissue biopsy before a cancer diagnosis can be established.

It cannot show tumour architecture

Pathologists diagnose many cancers partly by examining how cells are arranged, what they look like, how differentiated they are, and whether particular proteins are expressed in the tissue.

A ctDNA blood test cannot provide that structural information.

This is a major reason tissue biopsy remains indispensable for diagnosing and classifying many solid tumours.

It cannot guarantee that a detected mutation came from a tumour

Not every cancer-associated mutation detected in blood necessarily originates from cancer.

Age-related clones of blood-forming cells can develop genetic alterations, a phenomenon known as clonal haematopoiesis. These changes can sometimes resemble tumour-derived mutations and create misleading liquid-biopsy findings if testing and interpretation do not adequately distinguish their source. Recent reviews identify clonal haematopoiesis as an important potential source of false-positive results.

A liquid biopsy result is not simply “cancer detected” or “cancer absent.” Its meaning depends on why the test was ordered, the cancer type and stage, the specific biomarker being measured, how much tumour material reaches the blood, and whether the result is being used for treatment selection, monitoring, or experimental screening.

Can Liquid Biopsy Detect Cancer Early?

Liquid biopsy may eventually become an important tool for early cancer detection, but screening healthy people is a very different task from profiling a known cancer. As of September 2026, no multi-cancer detection blood test has been authorized by the U.S. FDA for population cancer screening.

Several multi-cancer detection, or MCD, tests are commercially available as laboratory-developed tests in the United States, but availability does not mean they have been shown to reduce cancer deaths. Regulatory status also differs between countries.

Why is early cancer harder to detect?

Early tumours are usually smaller, so they may release much less DNA into the circulation than advanced cancers.

That produces a difficult trade-off. A test must be sensitive enough to detect an extremely weak signal without becoming so permissive that normal biological changes are incorrectly classified as cancer.

NCI notes that many traditional circulating tumour markers have performed poorly for population screening because they may miss cancers or generate abnormal results in people who do not have cancer.

What are multi-cancer detection tests?

MCD tests attempt to search one blood sample for biological signals associated with multiple cancers. Depending on the platform, they may examine DNA mutations, abnormal DNA methylation patterns, proteins, or combinations of biomarkers.

The NCI information on multi-cancer detection blood tests states that randomized trials are still needed to determine whether currently available MCD approaches produce more benefit than harm when used to screen people without symptoms.

One crucial question is not simply whether these tests can find cancer. It is whether finding cancers through an MCD test ultimately reduces deaths while keeping false positives, unnecessary procedures, overdiagnosis, anxiety, and other harms acceptably low.

What a liquid biopsy result may—and may not—mean

Result or situation	What it may mean	What it does not prove
Actionable mutation found in a known cancer	A targeted treatment may be relevant, depending on the cancer and approved indication	That the treatment will definitely work
No mutation detected	The alteration may truly be absent, or there may be too little ctDNA in blood	That the tumour has no relevant mutations
ctDNA detected after treatment	Residual disease or higher recurrence risk may be present in certain settings	That visible metastatic disease is already present
ctDNA becomes undetectable during treatment	Tumour-derived DNA in blood has fallen below the assay's detection threshold	That every cancer cell has been eliminated
Positive multi-cancer screening signal	Further diagnostic investigation may be warranted	A confirmed cancer diagnosis
Negative multi-cancer screening result	No cancer signal was detected by that assay	That every type of cancer has been excluded

What Are the Benefits and Limitations of Liquid Biopsy?

The major attraction of liquid biopsy is that obtaining blood is much easier than repeatedly sampling a tumour. Its main weakness is that the information available in blood depends on what the tumour releases into the circulation.

Benefits of liquid biopsy

Potential advantages include:

• a simple blood draw rather than an invasive tumour procedure;

• easier repeat testing over time;

• molecular profiling when a tumour is difficult or unsafe to biopsy;

• possible detection of molecular changes from more than one tumour site;

• potential identification of resistance mutations;

• emerging possibilities for monitoring treatment and residual disease; and

• faster access to molecular information in some clinical settings.

These advantages make liquid biopsy particularly useful when tissue is unavailable or insufficient for molecular analysis.

Important limitations

The main limitations include:

• low ctDNA levels, especially with small tumours;

• false-negative results;

• possible false-positive findings;

• biological differences in how much DNA different cancers shed;

• differences between blood and tissue molecular findings;

• variation among laboratory platforms;

• lack of standardized use in some settings; and

• limited evidence that acting on certain emerging results improves outcomes.

A 2025 international expert perspective emphasized that reliable ctDNA testing requires standardized blood collection, DNA handling, assay validation, quality control, and careful interpretation.

Is liquid biopsy better than tissue biopsy?

Usually, “better” is the wrong comparison.

The tests answer overlapping but not identical questions. Blood testing can be particularly convenient for molecular profiling and repeated monitoring, while tissue provides direct pathological evidence about the tumour itself.

In many situations, the strongest strategy is to use them as complementary tools rather than expecting one to eliminate the need for the other.

When Might a Doctor Recommend a Liquid Biopsy?

A doctor may consider liquid biopsy when molecular information could affect cancer treatment and tissue is difficult to obtain, insufficient, or no longer representative of a changing tumour. The decision should be linked to a specific clinical question rather than ordering a broad cancer blood test “just in case.”

Possible situations include:

• advanced cancer requiring biomarker testing for targeted therapy;

• insufficient tissue for molecular profiling;

• a tumour location that makes biopsy difficult or risky;

• suspected treatment resistance;

• selected monitoring or residual-disease settings supported by evidence;

• enrolment in a clinical trial; or

• carefully considered use of an emerging test where limitations have been explained.

The regulatory status of individual assays and their approved uses varies between countries, cancers, biomarkers, and treatments.

What questions should patients ask before testing?

Before having a liquid biopsy, useful questions include:

• What exactly is this test looking for?

• Is the test being used to guide treatment, monitor disease, or screen for cancer?

• Is it validated for my particular cancer type?

• Is the test regulator-authorized for this specific use?

• What happens if the result is negative?

• Would I still need a tissue biopsy?

• What would happen after a positive result?

• Could the finding come from something other than my tumour?

• Will the result actually change my treatment?

These questions are particularly important for commercial early-detection tests because a technically measurable signal is not automatically evidence of improved health outcomes.

When Is Tissue Biopsy or Further Testing Still Necessary?

Tissue biopsy remains necessary in many patients to confirm that a suspicious lesion is cancer and determine exactly what kind of cancer it is. A liquid biopsy should not be used to dismiss a suspicious scan, persistent symptoms, or another clinical finding merely because the blood test is negative.

Further evaluation may be needed after:

• a positive screening blood test;

• a negative liquid biopsy when cancer remains clinically suspected;

• a blood test that does not detect a treatment-relevant mutation;

• conflicting blood and tissue results;

• new symptoms despite reassuring liquid-biopsy findings; or

• a result of uncertain significance.

A positive multi-cancer blood test is generally the beginning of a diagnostic process, not the final diagnosis.

Seek medical assessment rather than relying on a blood test alone if you have warning symptoms such as unexplained bleeding, a persistent or enlarging lump, unexplained weight loss, persistent changes in bowel habits, difficulty swallowing, prolonged unexplained cough, or another significant symptom that does not resolve. The appropriate investigation depends on the symptom and may involve examination, imaging, endoscopy, laboratory tests, or tissue biopsy.

Conclusion

A liquid biopsy for cancer can provide valuable molecular information from a blood sample, particularly when doctors are looking for treatment-relevant mutations or following selected cancers over time. Research into residual disease and early cancer detection is advancing quickly, but these applications are not equally established across cancer types.

The most important limitation is that tumours do not always release enough detectable material into blood. A negative result therefore cannot automatically exclude cancer, while a positive screening signal usually needs imaging or tissue confirmation. Liquid biopsy should be interpreted within a complete oncology assessment rather than used as a stand-alone answer. Discuss what a particular test can change in your care before having it performed.

Frequently Asked Questions

1. Can a liquid biopsy tell if I have cancer?

Sometimes it can detect cancer-related material, but a positive liquid biopsy does not always establish a definitive cancer diagnosis. The meaning depends on the test and clinical situation. For many suspected solid cancers, imaging and tissue biopsy are still needed to confirm what is present.

2. Can a negative liquid biopsy rule out cancer?

No. A tumour may release too little DNA into blood for the test to detect, particularly when it is small or has certain biological characteristics. Doctors may therefore recommend tissue testing or other investigations when cancer remains suspected despite a negative blood result.

3. Can liquid biopsy replace a tissue biopsy?

Not routinely. Blood testing can sometimes provide useful molecular information when tissue is difficult to obtain, but tissue remains essential for diagnosing and classifying many cancers. In practice, the two methods often complement each other rather than functioning as interchangeable alternatives.

4. Can a blood test detect several cancers at once?

Emerging multi-cancer detection tests are designed to search one blood sample for signals associated with several cancers. However, no MCD screening test is FDA-authorized in the United States as of September 2026, and randomized trials are still needed to establish overall benefits and harms.

5. Can liquid biopsy detect cancer recurrence earlier than a scan?

In some cancers and research settings, ctDNA can become detectable before recurrence is apparent on conventional imaging. That makes residual-disease testing promising, but its clinical role varies by cancer type. Earlier molecular detection does not automatically prove that changing treatment immediately will improve survival.

6. Does a positive ctDNA result always mean cancer is growing?

No. Interpretation depends on the clinical setting, assay and molecular finding. Some blood-cell mutations can mimic tumour-derived signals, while ctDNA may indicate residual disease without showing where a tumour is located. Results should therefore be interpreted by the oncology team alongside imaging, pathology and treatment history.